TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Patients willing to participate with confirmed diagnosis of COPD~* 40 years of age or older~* having a 10 pack year smoking history~* able to perform serial pulmonary function tests~* able to use both a Dry powder inhaler (DPI) and Respimat device~Exclusion criteria:~* Significant other disease~* clinically relevant abnormal hematology, chemistry, or urinalysis~* history of asthma~* diagnosis of thyrotoxicosis~* paroxysmal tachycardia related to beta agonists~* history of MI within 1 year, cardiac arrhythmia, hospitalization for heart failure within 1 year~* active tuberculosis, cystic fibrosis, clinically evident bronchiectasis~* significant alcohol or drug abuse~* pulmonary resection~* taking oral beta adrenergics~* taking unstable oral steroids~* daytime oxygen~* enrolled in rehabilitation program~* enrolled in another study or taking investigational products~* pregnant or nursing women, women of child bearing potential not willing to use two methods of birth control~* those who are not willing to comply with pulmonary medication washouts

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): olodaterol placebo and/or Tiotropium placebo inhaled once daily
- Olodaterol (BI1744) Low (Type: EXPERIMENTAL): Low dose inhaled orally once daily from Respimat inhaler
- Olodaterol (BI1744) High (Type: EXPERIMENTAL): High dose inhaled orally once daily from Respimat inhaler
- Tiotropium 18 mcg (Type: ACTIVE_COMPARATOR): 18mcg inhaled once daily from Handihaler

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria, Common to all MsFLASH Studies:~* Females aged 40-62 years.~* Menopausal, including:~  * Women with a uterus who have skipped 2 or more menstrual cycles with an amenorrhea interval ≥60 days in the past 12 months.~ * Women who have had a bi-lateral oophorectomy (surgical removal of both ovaries).~ * Women without a uterus who still have ovaries, under certain conditions determined during screening.~* Having bothersome hot flashes.~* In general good health as determined by medical history and physical measures.~* Signed informed consent.~Exclusion Criteria, Common to all MsFLASH Studies:~* Use of hormone therapy or hormonal contraceptives during the 2 months before enrollment and for the duration of the study. Certain exceptions apply, determined during screening.~* Use of any other therapy that is taken specifically for hot flashes, including prescription, over-the-counter, or herbal therapies in the past month and duration of the study.~* Any current severe or unstable medical illness.~* Uncontrolled hypertension (\>160/100) or resting heart rate \>110.~* History of endometrial or ovarian cancer; MI, angina, or cerebrovascular events.~* Pregnancy, intending pregnancy, breast feeding.~* Current participation in another drug trial or intervention study.~* Inability or unwillingness to complete the study procedures.~* Certain other conditions, determined during screening.~Exclusion Criteria, Specific to MsFLASH-01:~* Use of selective estrogen receptor modulators (SERMS) or aromatase inhibitors during the two months before enrollment.~* Use of gabapentin, pregabalin, triptans, warfarin (Coumadin®), or St. John's Wort.~* Known hypersensitivity to escitalopram (Lexapro®) or citalopram (Celexa®).~* Use of antidepressants during the past 30 days before starting Study 01, including SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and anxiolytics.~* Not using a medically approved method of birth control, if sexually active and not 12 or more months since last menstrual period.~* History of liver, gall bladder, renal disease, or uncontrolled seizure disorder.~* Certain other conditions, determined during screening.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 62 Years
- Healthy Volunteers: t

Study Arms:
- Escitalopram (Type: ACTIVE_COMPARATOR): Escitalopram is a selective serotonin reuptake inhibitor (SSRI)
- Placebo (Type: PLACEBO_COMPARATOR): Inactive pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Platelet Rich Plasma Injection Compared With Steroid Injection for the Treatment of Plantar Fasciitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patients having the pain over the plantar aspect of foot for more than 6 weeks with tenderness on palpation over the medial calcaneal tuberosity, failure of conservative treatment with physiotherapy, splints and NSAIDs.~Exclusion Criteria:~* Lumbar radiculopathy~* Existing trauma, previous surgery or any local pathology over the foot~* Patient on aspirin~* Bleeding disorders with low platelet counts~* Systemic disease like diabetes and rheumatoid arthritis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Platelet Rich Plasma (PRP) group (Type: EXPERIMENTAL): The PRP will be prepared based on the Sengodan et al, 2020 study.
- Steroid group (Type: ACTIVE_COMPARATOR): Steroid group will be treated with steroid injection. In this group, 2ml of Inj. Depo-Medrol 80 mg (Methylprednisolone) along with 1 ml lignocaine (0.25%) will be loaded in 5cc syringe and then the cocktail will be injected into medial calcaneal tuberosity at the most tender point using an aseptic technique as mentioned by Nishanth et.at,2018.~After the procedure, participants will be advised not to involve in any kind of rigorous activity with the affected foot for at least two days and then gradually return to their regular activities. All patients will be counseled to follow up in the next visit at 3 months and 6 months. The end-line information will be again recorded at 3 months and 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The ROVO Study: Radial Optic Neurotomy for CVO

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Onset of CVO not longer than 12 months~* On FLA 1. nonperfused - (greater than 10 disc area of nonperfusion) 2. perfused - visual acuity lower than 0.1 Snellen,or 3. perfused with no improvement of visual acuity over 4 weeks)~Exclusion Criteria:~* • Dense cataract\* (grade 3 and 4) which precludes judgement of the fundus.~  * Pregnancy~ * Allergy against Fluoresceine or Indocyanine green~ * Unable to come for follow up visit~ * Presence of other severe retinopathy or~ * Presence of advanced optic atrophy or uncontrolled glaucoma.~ * Visual acuity higher than 0.5 Snellen.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Diagnosis of active Rheumatoid Arthritis (RA) by standard criteria (American Rheumatism association (ARA) \[1987\] or American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) \[2010\]) at least 16 weeks prior to screening~* ACR global functional status class of 1 to 3~* Documented evidence of inadequate response tumor necrosis factor (TNF) inhibitors~* All subjects must have been receiving treatment with a minimum dose of 15 mg per week of Methotrexate for at least 12 weeks and at a stable dose for 28 days prior to screening. A dose as low as 10 mg Methotrexate is permitted if 15 mg could not be reached, due to toxicity. In Japan, Korea and Taiwan, a minimum dose of 7.5 mg per week is permitted. Additional treatment with Hydroxychloroquine or Chloroquine is permitted, if it is at a dose approved for the treatment of RA and the dose has been stable for at least 28 days prior to screening~* Minimum of 6 swollen and 6 tender joints on a 66/68 joint count at screening and at baseline (Day 1)~* Elevated High-sensitivity (hs) CRP and/or ESR~Exclusion Criteria:~* Active serious infection~* History of or active tuberculosis (TB)~* Elevated liver function tests (LFTs)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Clazakizumab (Dose # A) (Double-Blind) (Type: EXPERIMENTAL): Clazakizumab Dose # A injection by subcutaneous for 12 weeks + background Methotrexate
- Arm 2: Clazakizumab (Dose # B) (Double-Blind) (Type: EXPERIMENTAL): Clazakizumab Dose # B injection by subcutaneous for 12 weeks + background Methotrexate
- Arm 3: Clazakizumab (Dose # C) (Double-Blind) (Type: EXPERIMENTAL): Clazakizumab Dose # C injection by subcutaneous for 12 weeks + background Methotrexate
- Arm 4: Placebo matching with Clazakizumab (Double-Blind) (Type: EXPERIMENTAL): Clazakizumab Dose # D injection by subcutaneous for 12 weeks + background Methotrexate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.~* Severity of psoriasis disease meeting all of the following three criteria:~  * Psoriasis Area and Severity Index (PASI) score of 12 or greater~ * Investigator's Global Assessment (IGA) score of 3 or greater~ * Total body surface area (BSA) affected of 10% or greater~* Inadequate control by prior use of topical treatment, phototherapy and/or systemic therapy.~Exclusion criteria:~* Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate).~* Current drug-induced psoriasis.~* Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.~* Significant medical problems such as uncontrolled hypertension, congestive heart failure or a condition that significantly immunocompromises the subject.~* Hematological abnormalities.~* History of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis.~* History of lymphoproliferative disease or history of malignancy of any organ system within the past 5 years.~* Pregnant or nursing (lactating) women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects who were in placebo at Week 52 cannot continue in the extension treatment period
- Secukinumab 150 mg (Type: EXPERIMENTAL): After the data base lock of week 52 data has been performed, subjects received secukinumab 150 mg treatment as open label for the remainder of the extension treatment period.
- Secukinumab 300 mg (Type: EXPERIMENTAL): After the data base lock of week 52 data has been performed, subjects received secukinumab 300 mg treatment as open label for the remainder of the extension treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Traditional Chinese Medicine (TCM) for Temporomandibular Dysfunction (TMD): A Whole Systems Multi-site Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* TMD as diagnosed according to the Research Diagnostic Criteria-TMD by a trained dentist;~* worst facial pain greater than 5 out of 10.~Exclusion Criteria:~* prior surgery for TMD;~* life-threatening illnesses;~* conditions that would prevent participation in trial including consumption of Chinese herbs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TCM (Type: ACTIVE_COMPARATOR): Whole systems traditional Chinese medicine, including individually tailored herbal formulas, acupuncture, tuna (Chinese massage), lifestyle recommendations
- Self-care (Type: ACTIVE_COMPARATOR): Self-care for TMD developed by Dworkin, LeResche et al.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese participant diagnosed with compensated CHC GT 1~* Absence of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs or symptoms of advanced liver disease~* Has received and tolerated treatment with IFN-based therapy (IFN α, IFN β, or peg-IFN) with or without use of ribavirin, but failed to respond to the prior treatment (relapse or breakthrough)~* No evidence of cirrhosis~Exclusion Criteria:~* Co-infection with human immunodeficiency virus (HIV)~* Positive hepatitis B surface antigen or other evidence of active hepatitis B infection~* Any other condition that is contraindicated or for which caution is required for treatment with peg-IFN or RBV~* Any condition or pre-study laboratory abnormality, or history of any illness, that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering the study drugs, peg-IFN and RBV, to the participant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Vaniprevir 12 Week Arm (Type: EXPERIMENTAL): Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV
- Vaniprevir 24 Week Arm (Type: EXPERIMENTAL): Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
* Inclusion Criteria~  1. Male or non-pregnant female who previously participated in and completed two vaccinations in the V-122 Study.~ 2. Women of childbearing potential and men must agree to practice medically effective contraception during study period.~ 3. Able to understand the content and possible risks of informed consent and willing to sign the Informed Consent Form (ICF).~ 4. Able to understand and agrees to comply with all study procedures and be available for all study visits.~ 5. Ear temperature ≤ 38.0°C.~ 6. At screening visit, at least 6 months after first vaccination in the V-122 study.~* Exclusion Criteria~  1. Female who is pregnant or positive in pregnancy test at screening visit.~ 2. Female who is breast-feeding or plans to breastfeed within 90 days after booster vaccination.~ 3. Any acute illness, as determined by the study investigator 3 days before booster vaccination.~ 4. Prior administration of attenuated, nucleic acid (mRNA or DNA) or vectored vaccines in last 1 month before booster vaccination or expectation of such vaccines in the month after booster vaccination.~ 5. Prior administration of subunit vaccine or inactivated vaccine in last 14 days before booster vaccination or expectation of receipt of such vaccines in the 14 days after booster vaccination.~ 6. Any medical disease or condition that, in the opinion of the study investigator, may confound the results of the study or pose an additional risk to the subjects by their participation in the study.~ 7. Previous exposure to SARS-CoV-2 or receipt of an investigational or EUA vaccine product for the prevention of COVID-19, MERS or SARS except UB-612.~ 8. Subjects who take part in another clinical study, other than V-122 study, within 12 weeks prior to the day of informed consent.~ 9. Prior administration of immunoglobulins and/or any blood products in last 4 months before booster vaccination.~ 10. Prior chronic administration of immunosuppressant or corticosteroids, cytotoxic treatment in last 6 months before first vaccination.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- A group: 1 booster dose of UB-612 vaccine 100 μg (Type: EXPERIMENTAL): 1 booster dose for subjects at UB-612 vaccine 10 μg in V-122 study.
- B group: 1 booster dose of UB-612 vaccine 100 μg (Type: EXPERIMENTAL): 1 booster dose for subjects at UB-612 vaccine 30 μg in V-122 study.
- C group: 1 booster dose of UB-612 vaccine 100 μg (Type: EXPERIMENTAL): 1 booster dose for subjects at UB-612 vaccine 100 μg in V-122 study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18 years~2. Currently receiving cART and having received cART for a minimum of 1 year~3. HIV-1 plasma RNA \<50 copies/mL for at least 1 year (excluding viral load blips)~4. CD4 T cell count ≥500 cells/mm3~Exclusion Criteria:~1. CD4 T cell count nadir \<200 cells/mm3~2. Previous treatment with an HDACi (Histone deacetylase inhibitor) within the previous 6 months~3. Any evidence of an active AIDS-defining opportunistic infection, active HBV or HCV co-infection, significant cardiac disease, malignancy, transplantation, insulin dependent diabetes mellitus or other protocol defined excluded medical condition~4. Use of any protocol defined contraindicated medication or vaccination~5. Unacceptable values of the hematologic and clinical chemistry parameters as defined in the protocol.~6. Males or females who are unwilling or unable to use protocol defined methods of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A (Type: OTHER): Pre-treatment phase of 2-4 weeks (Visit 1- Visit 2a) followed by viral reactivation phase of 3 weeks (Visit 2 to Visit 7) consisting of one cycle of romidepsin infusions at a dosing of 5 mg/m2 on days 0, 7, and 14.~Post-activation phase of \~9 weeks (Visit 8 to Visit 11) to assess the effect of romidepsin on the size of latent HIV-1 reservoir.
- Part B (Type: OTHER): Pre-treatment phase of 2-4 weeks (Visit 1-Visit 2) followed by a therapeutic HIV-1 immunization phase of 12 weeks (Visit 2 to Visit 7) in which 1.2 mg Vacc-4x was administered together with 0.06 mg rhuGM-CSF at Visits 2, 3, 4, 5, 6 and 7 follow by a follow-up period of 2 weeks (Visit 8).~A viral reactivation phase of 3 weeks (Visit 9-Visit 11) consisting of one cycle of 3 romidepsin infusions (5 mg/m2) followed by a post-treatment observation phase of \~9 weeks (Visit 12-Visit 13) to assess the effect of the investigational treatment on the size of the latent HIV-1 reservoir.~A monitored antiretroviral pause of up to 16 weeks (Visit 14-Visit 33).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete